Kindeva Partners with Rocket Science Health to Advance Novel Intranasal CNS Drug Delivery Platform
Key Insights
Kindeva and Rocket Science Health (search) have formed a non-exclusive partnership to develop the RSH Olfactory Delivery Device, a dual nostril intranasal platform that precisely targets the olfactory clefts for direct CNS drug delivery.
The innovative device overcomes complex nasal anatomy challenges by ejecting a laminar stream rather than conventional plume sprays, with proprietary dispensing tips extending past the nasal valve for optimal drug deposition.
The technology is designed with human factors considerations for accessibility and accurate dosing, particularly benefiting cognitively and physically impaired patients requiring self-administration.
Kindeva, a global contract development and manufacturing organization (CDMO) specializing in drug delivery, has announced a strategic partnership with Canadian healthcare technology company Rocket Science Health (search) (RSH) to advance a novel intranasal delivery platform targeting central nervous system disorders. The collaboration aims to identify development partners for RSH's innovative olfactory delivery device while leveraging Kindeva's manufacturing and regulatory expertise.
Revolutionary Olfactory Targeting Technology
The RSH Olfactory Delivery Device represents a significant advancement in intranasal drug delivery, featuring a dual nostril platform designed to precisely target specific regions of the nasal cavity. The device's primary innovation lies in its ability to deposit the majority of a drug dose directly into the olfactory clefts, anatomical structures that provide direct access to the central nervous system but have historically been difficult to reach due to complex human nasal anatomy.
Early research suggests the device achieves superior drug deposition by ejecting a laminar stream, contrasting with conventional intranasal treatments that rely on plume sprays or mists. This targeted approach is enhanced by proprietary dispensing tips that extend past the nasal valve to reach an optimal vantage point for drug delivery.
Addressing Critical Clinical Needs
The technology addresses significant challenges in current intranasal delivery methods, particularly for patients with cognitive or physical impairments. Kenneth Irving, Rocket Science Health (search)'s Founder and CEO, explained the motivation behind the innovation: "A personal experience with an unreliable delivery method opened my eyes to the influence of drug devices on health outcomes. That realization led to the founding of Rocket Science Health and nearly a decade of rethinking intranasal delivery."
Irving emphasized the strategic importance of targeting specific nasal subregions: "Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the Olfactory Clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery."
Strategic Partnership Benefits
The non-exclusive agreement positions both companies to capitalize on the growing intranasal drug delivery market. Kindeva's comprehensive CDMO services, including manufacturing capabilities and regulatory pathway expertise, will be crucial for RSH's progression toward FDA approval and commercial readiness.
David Stevens, Chief Commercial and Operating Officer at Kindeva, highlighted the partnership's strategic value: "Kindeva's proven expertise and track record of developing and commercializing novel drug delivery devices makes us the ideal partner to support Rocket Science Health (search)'s new Olfactory device. I am incredibly excited to collaborate with the fantastic Rocket team as they look to realize their ambition to create a step change improvement in nasal drug delivery."
Clinical Development Pathway
RSH is preparing to advance the technology into clinical trials, focusing on dose-dependent medicine applications. The company's nearly decade-long development process has culminated in a device designed for accessibility, comfort, and accurate dosing across diverse patient populations.
Kindeva's global network of 10 manufacturing and R&D sites, including Annex 1-compliant aseptic fill finish capacity, will support the technology's development and eventual commercial distribution. The partnership extends RSH's global reach while providing the regulatory and manufacturing infrastructure necessary for successful market entry.
The collaboration represents a significant step forward in addressing unmet needs in CNS drug delivery, potentially offering new therapeutic options for patients requiring direct brain-targeted medication delivery through innovative intranasal technology.